How to buy Savara stock

Savara Inc is a biotechnology business based in the US. Savara shares (SVRA) are listed on the NASDAQ and all prices are listed in US Dollars. Savara employs 27 staff and has a trailing 12-month revenue of around 0.00.

Savara share price

Use our graph to track the performance of SVRA stocks over time.

Savara shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$1.00 - $3.17
50-day moving average	$1.87
200-day moving average	$1.51
Wall St. target price	$3.80
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.58

Buy Savara shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Savara stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Savara Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Savara financials

Revenue TTM	$257,000
Gross profit TTM	$-34,781,000
Return on assets TTM	-25.44%
Return on equity TTM	-59.75%
Profit margin	0%
Book value	$1.19
Market capitalisation	$212.8 million

TTM: trailing 12 months

Shorting Savara shares

There are currently 2.2 million Savara shares held short by investors – that's known as Savara's "short interest". This figure is 125.6% up from 986,965 last month.

There are a few different ways that this level of interest in shorting Savara shares can be evaluated.

Savara's "short interest ratio" (SIR)

Savara's "short interest ratio" (SIR) is the quantity of Savara shares currently shorted divided by the average quantity of Savara shares traded daily (recently around 9.7 million). Savara's SIR currently stands at 0.23. In other words for every 100,000 Savara shares traded daily on the market, roughly 230 shares are currently held short.

However Savara's short interest can also be evaluated against the total number of Savara shares, or, against the total number of tradable Savara shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Savara's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Savara shares in existence, roughly 20 shares are currently held short) or 0.0201% of the tradable shares (for every 100,000 tradable Savara shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Savara.

Find out more about how you can short Savara stock.

Savara share dividends

We're not expecting Savara to pay a dividend over the next 12 months.

Have Savara's shares ever split?

Savara's shares were split on 27 April 2017. This wouldn't directly have changed the overall worth of your Savara shares – just the quantity. However, indirectly, the new INF% higher share price could have impacted the market appetite for Savara shares which in turn could have impacted Savara's share price.

Savara share price volatility

Over the last 12 months, Savara's shares have ranged in value from as little as $0.9952 up to $3.17. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Savara's is 1.1419. This would suggest that Savara's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Savara overview

Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas. .

Frequently asked questions

• What percentage of Savara is owned by insiders or institutions?

  Currently 14.3% of Savara shares are held by insiders and 51.734% by institutions.

• How many people work for Savara?

  Latest data suggests 27 work at Savara.

• When does the fiscal year end for Savara?

  Savara's fiscal year ends in December.

• Where is Savara based?

  Savara's address is: Building III, Austin, TX, United States, 78746

• What is Savara's ISIN number?

  Savara's international securities identification number is: US8051111016

• What is Savara's CUSIP number?

  Savara's Committee on Uniform Securities Identification Procedures number is: 00764X103